2020

1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

   The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530